GlassScriptPhysician profile
Allison D Ernest
NPI 1235762964
$4,828.74
in general payments reported to CMS, 2019-2025
17 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,842 · 2022: $374 · 2023: $1,264 · 2024: $939 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.33 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $894.39 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $803.11 | 2021-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $637.80 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $555.52 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $343.27 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $329.75 | 2021-2025 | Invega, Spravato |
| Corium, LLC | $325.90 | 2023-2024 | Azstarys |
| Lundbeck LLC | $250.78 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $217.65 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $161.21 | 2023 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $134.47 | 2021-2024 | Fanapt |
| Axsome Therapeutics, INC. | $86.38 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $22.03 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $18.64 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $18.34 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $15.35 | 2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $14.15 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Ernest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.